{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:40:03Z","timestamp":1749494403143,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00520-025-09504-8","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:32:51Z","timestamp":1747117971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of renal function on non-hematologic toxicities in mCRC patients treated with TAS-102: a post-hoc analysis of the JASCC-CINV2001 study"],"prefix":"10.1007","volume":"33","author":[{"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hirate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Matsunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"9504_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"9504_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70:145\u2013164","journal-title":"CA Cancer J Clin"},{"key":"9504_CR3","first-page":"763","volume":"48","author":"A Matsuda","year":"2018","unstructured":"Matsuda A, Matsuda T, Shibata A et al (2018) Colorectal cancer epidemiology in Japan: mortality, incidence, survival. Jpn J Clin Oncol 48:763\u2013768","journal-title":"Jpn J Clin Oncol"},{"key":"9504_CR4","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H et al (2014) Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 32:2319\u20132326","journal-title":"Oncol Rep"},{"key":"9504_CR5","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","volume":"46","author":"K Sakamoto","year":"2015","unstructured":"Sakamoto K, Yokogawa T, Ueno H et al (2015) Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA. Int J Oncol 46:2327\u20132334","journal-title":"Int J Oncol"},{"key":"9504_CR6","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F et al (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545\u2013549","journal-title":"Int J Mol Med"},{"key":"9504_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","volume":"59","author":"M Fukushima","year":"2000","unstructured":"Fukushima M, Suzuki N, Emura T et al (2000) Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u2019-deoxyribonucleosides. Biochem Pharmacol 59:1227\u20131236","journal-title":"Biochem Pharmacol"},{"key":"9504_CR8","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized Trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"9504_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00520-024-08498-z","volume":"2","author":"H Fujii","year":"2024","unstructured":"Fujii H, Tsuchiya M, Watanabe D et al (2024) The emerging emetogenicity of trifluridine\/tipiracil (TAS-102) from patient self-reporting: a multicenter, prospective, observational study. Support Care Cancer 2:291","journal-title":"Support Care Cancer"},{"key":"9504_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bjc.2012.274","volume":"107","author":"T Doi","year":"2012","unstructured":"Doi T, Ohtsu A, Yoshino T et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107:429\u2013434","journal-title":"Br J Cancer"},{"key":"9504_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/cncr.22125","volume":"107","author":"DS Hong","year":"2006","unstructured":"Hong DS, Abbruzzese JL, Bogaard K et al (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107:1383\u20131390","journal-title":"Cancer"},{"key":"9504_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-016-2965-2","volume":"77","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Seraj J, Yoshida K et al (2016) Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol 77:515\u2013526","journal-title":"Cancer Chemother Pharmacol"},{"key":"9504_CR13","volume-title":"LONSURF (trifluridine and tipiracil) tablets, for oral use [prescribing information]","author":"T Oncology","year":"2019","unstructured":"Oncology T (2019) LONSURF (trifluridine and tipiracil) tablets, for oral use [prescribing information]. Taiho Oncology Inc, Princeton"},{"key":"9504_CR14","doi-asserted-by":"publisher","first-page":"17931","DOI":"10.1038\/s41598-023-45244-7","volume":"13","author":"M Shiroyama","year":"2023","unstructured":"Shiroyama M, Fukuoka S, Masuishi T et al (2023) Renal impairment as a risk factor for trifluridine\/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study. Sci Rep 13:17931","journal-title":"Sci Rep"},{"key":"9504_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/jjco\/hyaa243","volume":"51","author":"T Yoshino","year":"2021","unstructured":"Yoshino T, Uetake H, Funato Y et al (2021) Post-marketing surveillance study of trifluridine\/tipiracil in patients with metastatic colorectal cancer. Jpn J Clin Oncol 51:700\u2013706","journal-title":"Jpn J Clin Oncol"},{"key":"9504_CR16","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1:1051\u20131059","journal-title":"JAMA Oncol"},{"key":"9504_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993\u20131001","journal-title":"Lancet Oncol"},{"key":"9504_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-021-04308-z","volume":"88","author":"MW Saif","year":"2021","unstructured":"Saif MW, Becerra CR, Fakih MG et al (2021) A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemother Pharmacol 88:485\u2013497","journal-title":"Cancer Chemother Pharmacol"},{"key":"9504_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","volume":"20","author":"DL Hilarius","year":"2012","unstructured":"Hilarius DL, Kloeg PH, van der Wall E et al (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20:107\u2013117","journal-title":"Support Care Cancer"},{"key":"9504_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711\u2013717","journal-title":"Cancer Sci"},{"key":"9504_CR21","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(14)70006-3","volume":"15","author":"J Andreyev","year":"2014","unstructured":"Andreyev J, Ross P, Donnellan C et al (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol 15:e447\u2013e460","journal-title":"Lancet Oncol"},{"key":"9504_CR22","doi-asserted-by":"publisher","first-page":"e014916","DOI":"10.1136\/bmjopen-2016-014916","volume":"7","author":"C Deng","year":"2017","unstructured":"Deng C, Deng B, Jia L et al (2017) Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review. BMJ Open 7:e014916","journal-title":"BMJ Open"},{"key":"9504_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1634\/theoncologist.5-3-250","volume":"5","author":"RB Arbuckle","year":"2000","unstructured":"Arbuckle RB, Huber SL, Zacker C (2000) The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5:250\u2013259","journal-title":"Oncologist"},{"key":"9504_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12882-022-02893-6","volume":"23","author":"D Karahan","year":"2022","unstructured":"Karahan D, \u015eahin \u0130 (2022) Comparison of gastrointestinal symptoms and findings in renal replacement therapy modalities. BMC Nephrol 23:261","journal-title":"BMC Nephrol"},{"key":"9504_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/toxins13040252","volume":"13","author":"J Rysz","year":"2021","unstructured":"Rysz J, Franczyk B, \u0141awi\u0144ski J et al (2021) The impact of CKD on uremic toxins and gut microbiota. Toxins (Basel) 13:252","journal-title":"Toxins (Basel)"},{"key":"9504_CR26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-Tipiracil and Bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T18:03:12Z","timestamp":1749492192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["9504"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09504-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Fujii has received honoraria for lectures from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd.M Tsuchiya has received honoraria for lectures from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Sun Pharm and Kyowa Kirin.D Watanabe has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd.D Hirate has received honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo, Eli Lilly and Company, Pfizer Eisai, Takeda Pharmaceutical Co., Ltd., Bristol Myers Squibb., EA Pharmaceutical Co., Ltd., MSD Japan, Kyowa Kirin, Chugai Pharmaceutical Co., Ltd., Yakult Honsha., Nippon Kayaku., Eisai., Meiji Seika Pharmaceutical Co., Ltd., Merck Bio Pharmaceutical Co., Ltd., AstraZeneca plc. and Sun Pharma.Y Ando has received honoraria for lectures from Yakult Honsha., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo, and Pfizer Eisai.N Matsunami has received honoraria for lectures from Pfizer Eisai, Daiichi Sankyo and Eli Lilly and Company. N Matsuhashi has received both honoraria for lectures and grants made to the institution from Taiho Pharmaceutical Co., Ltd.J Nishimura has received honoraria for lectures from Taiho Pharmaceutical Co., Ltd.N Inui has received honoraria for lectures from Taiho Pharmaceutical Co., Ltd., AstraZeneca plc and Chugai Pharmaceutical Co., Ltd.A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharmaceutical Co., Ltd., Daiichi Sankyo, Pfizer Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka Pharmaceutical Co., Ltd., Sandoz, Tsumura, Nipro, Taiho Pharmaceutical Co., Ltd., Kyowa Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim; grants made to institution from Nippon Kayaku, Asahi Kasei Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., Sun Pharma; and consulting fees from Nippon Kayaku.H Iihara has received honoraria for lectures from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha., Astellas Pharmaceutical Co., Ltd., Eli Lilly and Company, Daiichi Sankyo., AstraZeneca plc, Nippon Kayaku, Ono Pharmaceutical Co., Ltd., and Nippon Boehringer Ingelheim; and consulting fees from Pfizer Eisai and Taiho Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"469"}}